UA127860U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis involves conducting a clinical examination, study of cholesterol levels of low and high density lipoproteins, arteriography. In the serum determine the polymorphism of the gene MTHFR C677T, the content of endothelin, folic acid, oxyproline, PSA, homocysteine. With homozygous carrier 677-TT, endothelin levels> 10 ng / ml, folic acid <6 ng / ml, oxyproline> 15 μmol / l, PSA> 6 mg / l, homocysteine> 20 μmol / l diagnose the development of atherosclerosis.

Description

The proposed method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of low- and high-density lipoprotein cholesterol levels, arteriography (Okorokov A.N.

Diagnosis of diseases of internal organs. - Vol. 6. - P. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that along with the study of low- and high-density lipoprotein cholesterol levels, the polymorphism of the methylenetetrahydrofolate reductase gene (MITNEV Sb677T), the content of endothelin, folic acid, oxyproline, C-reactive protein (CRP), and homocysteine are determined in the patient's blood serum by arteriography. At a homozygous carrier of 677-TT, levels of endothelin 210 ng/ml, folic acid 6 ng/ml, oxyproline 215 μmol/l, SRP 26 mg/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

Application of the method

During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. In the blood serum of the patient, the MTNEV C677T gene polymorphism is determined. The content of endothelin, folic acid, oxyproline, SRP, homocysteine is determined by immunoenzymatic method. With homozygous carrier 677-TT, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP "6 mg/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

A specific example of using the method

Patient K., 49 years old, was hospitalized in the clinic with a diagnosis of rheumatoid arthritis. Examined

Low and high density lipoprotein cholesterol levels were studied. Vascular arteriography was performed. No signs of atherosclerosis were detected. Polymorphism of MTNEVK C677T gene was determined in blood serum. The content of endothelin was determined by the immunoenzymatic method,

From folic acid, oxyproline, SRP, homocysteine. Homozygous carrier 677-1TT was established.

Levels of endothelin - 17.8 ng/ml, folic acid - 2.6 ng/ml, oxyproline - 21 μmol/l, SRP - 15 mg/l, homocysteine - 30 μmol/l. The development of atherosclerosis was diagnosed. Arteriographic confirmation of the diagnosis was obtained only after 12 months.

Thus, the proposed method makes it possible to establish a diagnosis at the early stages of the development of the process.

Claims (1)

FORMULA OF A USEFUL MODEL Method of diagnosing the development of atherosclerosis, which includes conducting a clinical examination, 40 studies of low- and high-density lipoprotein cholesterol levels, arteriography, which is distinguished by the fact that the MTNEV Sb677T gene polymorphism, the content of endothelin, folic acid, oxyproline, SRP, homocysteine, and in homozygous carrier 677-TT, endothelin levels of 210 ng are determined in the blood serum /ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP 26 mg/l, homocysteine 220 μmol/l diagnose the development of atherosclerosis.